Opinion|Videos|July 1, 2024
Clinical Implications of MajesTEC-1
Author(s)Amrita Y. Krishnan, MD, Binod Dhakal, MD, MS
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.
Advertisement
Video content above is prompted by the following questions:
- Based on the long-term efficacy and safety data presented for teclistamab in the MajesTEC-1 trial, what are your key takeaways or clinical implications for the use of this agent in patients with relapsed/refractory multiple myeloma (R/R MM)?
- Despite the promising results with teclistamab, what potential unmet needs or areas for further research and development remain in the treatment of R/R MM?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5